Paolo Tarantino: Make sure not to miss our presentation of RELIEVE at the San Antonio Breast Cancer Symposium (SABCS23)

Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter:

“Trastuzumab Deruxtecan (T-DXd) outperformed chemo for the treatment of HER2-low Metastatic Breast Cancer (MBC). But how does it perform among patients with dynamic changes in HER2 status? Does it also work if the most recent biopsy was HER2-0? Make sure not to miss our presentation of RELIEVE at the San Antonio Breast Cancer Symposium (SABCS23)!”

Source: Paolo Tarantino/Twitter